Kennedy Rx Bill Would Require Phase IV Studies To Resolve Safety Issues
This article was originally published in The Pink Sheet Daily
Executive Summary
The mandatory post-marketing studies would be designed to confirm or refute a “significant safety issue” with either a drug or its class; the results would be publicized. The bill also directs GAO to conduct a comprehensive study on drug safety oversight.